Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain ...

Multibagger stock: Titan Biotech shares surged 20% to ₹312 after a 1:5 stock split, enhancing liquidity and making shares ...

Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Moleculin is currently advancing a Phase 3 clinical trial called MIRACLE, evaluating its lead program Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid ...